2020
AML-123: Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Engraftment in Older Patients with Active, Relapsed, or Refractory (rel/ref) AML: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 SIERRA Trial
Gyurkocza B, Nath R, Stiff P, Agura E, Litzow M, Tomlinson B, Choe H, Abhyankar S, Seropian S, Chen G, Hari P, Al-Kadhimi Z, Foran J, Orozco J, Van Besien K, Sabloff M, Kebriaei P, Abboud C, Levy M, Lazarus H, Giralt S, Berger M, Reddy V, Pagel J. AML-123: Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Engraftment in Older Patients with Active, Relapsed, or Refractory (rel/ref) AML: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 SIERRA Trial. Clinical Lymphoma Myeloma & Leukemia 2020, 20: s182. DOI: 10.1016/s2152-2650(20)30716-3.Peer-Reviewed Original ResearchCC armOlder patientsTransplant ratesLower transplant-related mortalityIncidence of gradeNon-relapse mortalityTransplant-related mortalityMajority of patientsFavorable safety profileFebrile neutropeniaInduction therapyPrior therapyActive diseaseRefractory AMLSalvage therapyDurable responsesGraft failureInfusion reactionsEngraftment dataMedian ageSafety profilePatient populationAdvanced ageDisease progressionGrade 3Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes
Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes. CHEST Journal 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.Peer-Reviewed Original ResearchConceptsCytokine release syndromeTocilizumab-treated patientsSevere diseaseRelease syndromeTocilizumab treatmentInflammatory biomarkersNonsevere diseaseSoluble IL-2 receptor levelsHigh-sensitivity C-reactive proteinIL-2 receptor levelsConsecutive COVID-19 patientsIL-6 receptor antagonistMechanical ventilation outcomesC-reactive proteinCOVID-19 patientsHigher admission levelsRace/ethnicityMV daysVentilation outcomesAdverse eventsChart reviewClinical responseMedian ageWhite patientsClinical outcomes
2009
Autologous and allogeneic transplantation for aggressive T-cell lymphomas: A single institution experience
Lansigan F, Cooper D, Seropian S, Foss F. Autologous and allogeneic transplantation for aggressive T-cell lymphomas: A single institution experience. Journal Of Clinical Oncology 2009, 27: 8558-8558. DOI: 10.1200/jco.2009.27.15_suppl.8558.Peer-Reviewed Original ResearchAggressive T-cell lymphomaProgression-free survivalT-cell lymphomaAuto groupFirst remissionBetter progression-free survivalAggressive B-cell lymphomasMedian prior therapiesNon-relapse mortalitySingle institution experienceRole of transplantationNon-Hodgkin lymphomaLarge cell transformationB-cell lymphomaAllo transplantPrior therapyRelapse mortalityRelapsed diseaseALLO groupPoor OSAllogeneic transplantationLymphoblastic lymphomaMedian ageMedian timeWorse prognosis
2008
Should All Patients with Acute Myelogenous Leukemia (AML) Other Than Good Risk Cytogenetics Receive Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in First Remission?
Alpdogan O, Lenox R, Barile A, Foss F, Shlomchik W, Reuben C, Cooper D, Seropian S. Should All Patients with Acute Myelogenous Leukemia (AML) Other Than Good Risk Cytogenetics Receive Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in First Remission? Blood 2008, 112: 4396. DOI: 10.1182/blood.v112.11.4396.4396.Peer-Reviewed Original ResearchAllogeneic HSCTUnrelated donorsTransplant related mortalityEffective curative therapyPoor prognostic featuresConditioning protocolFirst remissionElderly patientsSecondary AMLStandard therapySupportive careCurative therapyMedian ageRelated donorsPrognostic featuresAdvanced ageDonor selectionRelated mortalityRI groupMyeloproliferative diseasePatientsIntensity protocolAMLHSCTTherapy